Case Series: Unilateral Amygdala Ablation Ameliorates Post-Traumatic Stress Disorder Symptoms and Biomarkers.
Ablation
Amygdala
Anxiety
Epilepsy
Hippocampus
Lesion
Post-traumatic stress disorder
Resection
Journal
Neurosurgery
ISSN: 1524-4040
Titre abrégé: Neurosurgery
Pays: United States
ID NLM: 7802914
Informations de publication
Date de publication:
15 09 2020
15 09 2020
Historique:
received:
11
10
2019
accepted:
12
01
2020
pubmed:
8
4
2020
medline:
26
1
2021
entrez:
8
4
2020
Statut:
ppublish
Résumé
Post-traumatic stress disorder is a severe psychobiological disorder associated with hyperactivity of the amygdala, particularly on the right side. Highly selective laser ablation of the amygdalohippocampal complex is an effective neurosurgical treatment for medically refractory medial temporal lobe epilepsy that minimizes neurocognitive deficits relative to traditional open surgery. To examine the impact of amygdalohippocampotomy upon symptoms and biomarkers of post-traumatic stress disorder. Two patients with well-documented chronic post-traumatic stress disorder who subsequently developed late-onset epilepsy underwent unilateral laser amygdalohippocampotomy. Prospective clinical and neuropsychological measurements were collected in patient 1. Additional prospective measurements of symptoms and biomarkers were collected pre- and post-surgery in patient 2. After laser ablation targeting the nondominant (right) amygdala, both patients experienced not only reduced seizures, but also profoundly abated post-traumatic stress symptoms. Prospective evaluation of biomarkers in patient 2 showed robust improvements in hyperarousal symptoms, fear potentiation of the startle reflex, brain functional magnetic resonance imaging responses to fear-inducing stimuli, and emotional declarative memory. These observations support the emerging hypothesis that the right amygdala particularly perpetuates the signs and symptoms of post-traumatic stress disorder and suggests that focal unilateral amydalohippocampotomy can provide therapeutic benefit.
Sections du résumé
BACKGROUND
Post-traumatic stress disorder is a severe psychobiological disorder associated with hyperactivity of the amygdala, particularly on the right side. Highly selective laser ablation of the amygdalohippocampal complex is an effective neurosurgical treatment for medically refractory medial temporal lobe epilepsy that minimizes neurocognitive deficits relative to traditional open surgery.
OBJECTIVE
To examine the impact of amygdalohippocampotomy upon symptoms and biomarkers of post-traumatic stress disorder.
METHODS
Two patients with well-documented chronic post-traumatic stress disorder who subsequently developed late-onset epilepsy underwent unilateral laser amygdalohippocampotomy. Prospective clinical and neuropsychological measurements were collected in patient 1. Additional prospective measurements of symptoms and biomarkers were collected pre- and post-surgery in patient 2.
RESULTS
After laser ablation targeting the nondominant (right) amygdala, both patients experienced not only reduced seizures, but also profoundly abated post-traumatic stress symptoms. Prospective evaluation of biomarkers in patient 2 showed robust improvements in hyperarousal symptoms, fear potentiation of the startle reflex, brain functional magnetic resonance imaging responses to fear-inducing stimuli, and emotional declarative memory.
CONCLUSION
These observations support the emerging hypothesis that the right amygdala particularly perpetuates the signs and symptoms of post-traumatic stress disorder and suggests that focal unilateral amydalohippocampotomy can provide therapeutic benefit.
Identifiants
pubmed: 32259241
pii: 5817377
doi: 10.1093/neuros/nyaa051
pmc: PMC7593359
doi:
Types de publication
Case Reports
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
796-802Subventions
Organisme : NCATS NIH HHS
ID : KL2 TR002381
Pays : United States
Organisme : NINDS NIH HHS
ID : R21 NS104953
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR002378
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH100122
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS088748
Pays : United States
Organisme : NIMH NIH HHS
ID : K01 MH116364
Pays : United States
Commentaires et corrections
Type : CommentIn
Type : CommentIn
Informations de copyright
Copyright © 2020 by the Congress of Neurological Surgeons.
Références
Psychiatry Res. 2009 May 15;167(1-2):151-60
pubmed: 19345420
Am J Psychiatry. 2005 Feb;162(2):214-27
pubmed: 15677582
Acta Psychiatr Scand. 2006 Apr;113(4):360-3; discussion 363-4
pubmed: 16638081
J Psychiatr Res. 2013 Oct;47(10):1469-78
pubmed: 23827769
JAMA. 2000 Apr 12;283(14):1837-44
pubmed: 10770145
Psychol Assess. 2008 Jun;20(2):131-8
pubmed: 18557690
Ann N Y Acad Sci. 2010 Oct;1208:142-9
pubmed: 20955336
Ann Neurol. 2018 Mar;83(3):575-587
pubmed: 29420840
Neuropsychopharmacology. 2016 Mar;41(4):1156-65
pubmed: 26289143
Arch Gen Psychiatry. 2001 May;58(5):485-92
pubmed: 11343529
Gen Hosp Psychiatry. 2009 Nov-Dec;31(6):505-14
pubmed: 19892208
Front Psychiatry. 2016 Sep 14;7:156
pubmed: 27683563
Nat Neurosci. 2008 Feb;11(2):232-7
pubmed: 18157125
Arch Gen Psychiatry. 2005 Jun;62(6):593-602
pubmed: 15939837
J Abnorm Psychol. 2008 May;117(2):479-84
pubmed: 18489226
Neuroimage Clin. 2017 Nov 21;17:650-658
pubmed: 29204343
Am J Psychiatry. 2017 Dec 1;174(12):1163-1174
pubmed: 28715908
Psychosom Med. 2017 Jul/Aug;79(6):664-669
pubmed: 28306623